Radiation Exposure to the Nuclear Medicine personnel during preparation and handling of 213Bi- radiopharmaceuticals.

Conclusion: The study shows that the use of 213Bi-PSMA/DOTATOC for the therapy of CRPC and NET, respectively, has been convenient, safe and straightforward. The external radiation doses to the occupational workers involved in different procedures were far below the dose limits prescribed by the Regulatory Authority (20mSv/yr). The dose rates from the treated patients showed no detrimental effect on public and environment. PMID: 31604889 [PubMed - as supplied by publisher]
Source: Journal of Nuclear Medicine Technology - Category: Nuclear Medicine Tags: J Nucl Med Technol Source Type: research